Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tonix Pharmaceuticals Holding Corp. before investing.

In this article, we go over a few key elements for understanding Tonix Pharmaceuticals Holding Corp.’s stock price such as:

• Tonix Pharmaceuticals Holding Corp.’s current stock price and volume
• Why Tonix Pharmaceuticals Holding Corp.’s stock price changed recently
• Upgrades and downgrades for TNXP from analysts
• TNXP’s stock price momentum as measured by its relative strength

About Tonix Pharmaceuticals Holding Corp. (TNXP)

Before we jump into Tonix Pharmaceuticals Holding Corp.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Want to learn more about Tonix Pharmaceuticals Holding Corp.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Tonix Pharmaceuticals Holding Corp..

Tonix Pharmaceuticals Holding Corp.’s Stock Price as of Market Close

As of April 20, 2026, 4:00 PM, CST, Tonix Pharmaceuticals Holding Corp.’s stock price was $14.340.

Tonix Pharmaceuticals Holding Corp. is up 2.58% from its previous closing price of $13.980.

During the last market session, Tonix Pharmaceuticals Holding Corp.’s stock traded between $13.700 and $14.440. Currently, there are approximately 11.80 million shares outstanding for Tonix Pharmaceuticals Holding Corp..

Tonix Pharmaceuticals Holding Corp.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Tonix Pharmaceuticals Holding Corp. Stock Price History

Tonix Pharmaceuticals Holding Corp.’s (TNXP) price is currently up 4.29% so far this month.

During the month of April, Tonix Pharmaceuticals Holding Corp.’s stock price has reached a high of $14.900 and a low of $12.190.

Over the last year, Tonix Pharmaceuticals Holding Corp. has hit prices as high as $69.970 and as low as $11.603. Year to date, Tonix Pharmaceuticals Holding Corp.’s stock is down 8.19%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Tonix Pharmaceuticals Holding Corp. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 20, 2026, there were 0 analysts who downgraded Tonix Pharmaceuticals Holding Corp.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Tonix Pharmaceuticals Holding Corp.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Tonix Pharmaceuticals Holding Corp.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Tonix Pharmaceuticals Holding Corp.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Tonix Pharmaceuticals Holding Corp. (TNXP) by visiting AAII Stock Evaluator.

Relative Price Strength of Tonix Pharmaceuticals Holding Corp.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 20, 2026, Tonix Pharmaceuticals Holding Corp. has a weighted four-quarter relative price strength of 5.99%, which translates to a Momentum Score of 72 and is considered to be Strong.

Want to learn more about how Tonix Pharmaceuticals Holding Corp. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Tonix Pharmaceuticals Holding Corp. Stock Price: Bottom Line

As of April 20, 2026, Tonix Pharmaceuticals Holding Corp.’s stock price is $14.340, which is up 2.58% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Tonix Pharmaceuticals Holding Corp. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.